Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis.
about
Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds.Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogramA comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations.Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunctionPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Year in review in Intensive Care Medicine 2013: III. Sepsis, infections, respiratory diseases, pediatrics.Pharmacokinetic considerations for drugs administered in the critically ill.Effects of Low-Dose Escherichia coli Lipopolysaccharide-Induced Endotoxemia on Morphine Pharmacokinetics in an Animal Model.Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing.Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing.Delivering precision antimicrobial therapy through closed-loop control systems.The pharmacokinetics of vancomycin in patients with severe acute pancreatitis.
P2860
Q34739945-7274A5F8-AA27-4FA7-A9B2-5F6A47BF4733Q34777837-5FE3B252-447E-4739-91CA-A6FC1581A75DQ35041939-CEEF0DC5-3E77-4639-9480-2C5AAD0DD496Q35124710-2FBEE966-75B8-4309-91BE-0C8A43184B02Q35676081-A240F5B8-BB15-474E-9B22-46793E5B9D48Q36083619-1C05A5FC-4806-4130-88A9-97CE8C1B1F88Q38138835-3928CC50-41BA-48EE-B92D-0E2E57D34F7BQ38187368-1F860617-0A6C-4DE1-8F2A-AAB4559BBF36Q38351793-678DAFF8-6935-4409-BC28-3ED7DE87C4D3Q40057969-374AA117-7C07-4E5B-A726-692E95CF1123Q40695076-AB348AA6-9F30-49C7-84DF-C1E12D3B65FFQ42228348-88DDDD11-6739-4841-831B-87224F649EECQ42236097-7669B030-AD53-4870-9A92-FC4EC58C3122Q44923981-746FECBF-0A13-4779-8A64-9242BEA105DCQ47276911-7329943B-FDA5-43CF-9E12-C9E6E801DBD6Q50707463-DE46D35C-D366-4CBB-93E6-0A6CE3AFE132
P2860
Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Systemic inflammatory response ...... ement in patients with sepsis.
@en
Systemic inflammatory response ...... ement in patients with sepsis.
@nl
type
label
Systemic inflammatory response ...... ement in patients with sepsis.
@en
Systemic inflammatory response ...... ement in patients with sepsis.
@nl
prefLabel
Systemic inflammatory response ...... ement in patients with sepsis.
@en
Systemic inflammatory response ...... ement in patients with sepsis.
@nl
P2093
P2860
P1476
Systemic inflammatory response ...... ement in patients with sepsis.
@en
P2093
Daikai Sadamitsu
Katsuya Komori
Kazuhiko Tanaka
Tsuyoshi Fukuda
Yuko Shimamoto
P2860
P2888
P304
P356
10.1007/S00134-013-2909-9
P577
2013-04-20T00:00:00Z
P6179
1041975219